They offer a range of products, including Revacept, a human Fc fusion protein that prevents platelet activation at vascular injury sites, COR-2, a protein that interferes with foam cell generation, and COR-3, a protein that binds to atherosclerotic plaques and circulating progenitor cells for accelerated plaque healing. With a comprehensive product pipeline, advanceCOR covers all aspects from research to commercialization, providing individuals with personalized treatment options for cardiovascular diseases.